Stocks · News reference

Genelux Announces Publication Of Translational And Clinical Findings From Phase 1b/2 VIRO-15 Trial Of Olvi-Vec-Primed Immunochemotherapy In Heavily Pretreated Patients With Platinum-R/R Ovarian Cancer

Jun 30, 2026, 12:02 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 13, 2026, 8:33 PMBenzinga Newsdesk
Genelux Q2 EPS $(0.21) Misses $(0.19) Estimate
Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 5 percent decrease over losses of $(0.20) per share from the same
Read original at benzinga
GNLX